| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Clinical Biochemistry, Herlev University Hospital (H.H.W., R.V.A., B.G.N.), DK-2730 Herlev, Denmark; Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital (A.T.-H.), DK-2100 Copenhagen, Denmark; and Copenhagen City Heart Study, Bispebjerg University Hospital (A.T.-H., G.B.J., B.G.N.), DK-2400 Copenhagen, Denmark
Address all correspondence and requests for reprints to: Dr. Børge G. Nordestgaard, Department of Clinical Biochemistry, Herlev University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark. E-mail: brno{at}herlevhosp.kbhamt.dk.
Context: Genetic variants in lipoprotein lipase may affect triglycerides, high-density lipoprotein (HDL), and risk of ischemic heart disease (IHD).
Objective: The objective of this study was to investigate the influence of T(93)G, G(53)C, Asp9Asn, Gly188Glu, Asn291Ser, and Ser447Ter lipoprotein lipase genotypes on triglycerides, HDL, and IHD.
Design: The cross-sectional study involved 9004 adults. The prospective study consisted of 8817 adults developing 1001 IHD events over 23 yr. The case-control study involved 7818 non-IHD individuals vs. cohorts of 915 and 1062 IHD patients, respectively.
Setting: The study was performed in the Danish general population (the Copenhagen City Heart Study).
Participants: IHD was angina pectoris or myocardial infarction.
Main Outcome Measures: Triglycerides, HDL, and IHD were the main outcome measures.
Results: Cross-sectionally, triglycerides varied by genotype with 1.27 mmol/liter in women and 1.22 mmol/liter in men. HDL cholesterol varied by genotype with 0.49 mmol/liter in women and 0.60 mmol/liter in men. Prospectively, 9Asn (with 93G) heterozygotes and homozygotes combined vs. noncarriers had a hazard ratio for IHD of 1.6 [95% confidence interval (CI), 1.22.3]; 291Ser and 447Ter did not change IHD risk. In the case-control study, combining the cohorts of IHD patients, 9Asn (with 93G) heterozygotes and homozygotes combined vs. noncarriers had an odds ratio for IHD of 1.5 (CI, 1.22.1). 291Ser and 447Ter did not change IHD risk. Stratified for apolipoprotein E genotype, the odds ratios for IHD in 9Asn (with 93G) heterozygotes and homozygotes combined vs. noncarriers were 2.6 (CI, 1.25.5) among
32 individuals and 2.4 (CI, 1.44.1) among
43 individuals.
Conclusions: Genetic variation in lipoprotein lipase is associated with differences in plasma triglycerides greater than 1 mmol/liter and differences in HDL cholesterol greater than 0.5 mmol/liter. A 1.6-fold risk of IHD in 9Asn (with 93G) heterozygotes and homozygotes combined is influenced by apolipoprotein E genotype.
This article has been cited by other articles:
![]() |
R. Frikke-Schmidt, B. G. Nordestgaard, M. C. A. Stene, A. A. Sethi, A. T. Remaley, P. Schnohr, P. Grande, and A. Tybjaerg-Hansen Association of Loss-of-Function Mutations in the ABCA1 Gene With High-Density Lipoprotein Cholesterol Levels and Risk of Ischemic Heart Disease JAMA, June 4, 2008; 299(21): 2524 - 2532. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kathiresan, O. Melander, D. Anevski, C. Guiducci, N. P. Burtt, C. Roos, J. N. Hirschhorn, G. Berglund, B. Hedblad, L. Groop, et al. Polymorphisms Associated with Cholesterol and Risk of Cardiovascular Events N. Engl. J. Med., March 20, 2008; 358(12): 1240 - 1249. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |